Oct. 17, 2024 — Researchers discovered they could boost survival to 92% for patients with advanced Hodgkin lymphoma by adding the immunotherapy nivolumab to a current treatment regimen.

The committee reviewed data showing a 94 percent complete response rate as a third- or later-line treatment for refractory follicular lymphoma.

Cancer survivor Zoe Plastiras hopes her message provides some reassurance by highlighting advances in cancer treatment.

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

Dan Evans, 19, from Newark in Nottinghamshire, described his huge relief ringing the "cancer-free bell" at the teenage cancer ...

However, leukemia originates in the bone marrow and spreads through the blood, while lymphoma originates in the spleen or lymph nodes and spreads through the lymph vessels. Leukemia and lymphoma can ...

Hodgkin lymphoma (formerly known as Hodgkin disease), which involves an abnormal type of lymphocyte called Reed-Sternberg cells Non-Hodgkin lymphoma, which does not contain Reed-Sternberg cells ...

Concurrently, mediastinal lymphadenopathy was observed. Given the suspicion of mediastinal lymphoma, a mediastinoscopy with lymph node biopsy was performed. Following a negative biopsy result, ...

Several nonprofit organizations, such as the American Cancer Society, Cancer Care, CLL Society, and the Leukemia and Lymphoma Society provide ways for people with CLL to connect with others.

Although usually identified early, skin lymphomas can be mistaken for other skin conditions, delaying diagnosis. Non-Hodgkin's lymphoma (NHL) occurs when lymphocytes called T cells and B cells become ...

Breyanzi ® offers diffuse large B-cell lymphoma patients facing relapse or refractory disease earlier access with more personalized second-line treatment options. In the pivotal Phase 3 TRANSFORM ...